Drug safety provisions in US and Europe outshine Canada

Silversides, Ann
January 2010
CMAJ: Canadian Medical Association Journal;1/12/2010 Supplement, Vol. 182, pE23
Academic Journal
The article reports that new drug safety provisions are earning profits in the U.S. and Europe but the legislation to introduce new regulations in Canada are getting weakened. It is stated that U.S. Food and Drug Administration (FDA) is taking drug safety to a higher level and several new initiatives are being launched in the US to actively monitor drug safety.


Related Articles

  • Too Many Solutions. Clinton, Patrick // Pharmaceutical Executive;Mar2005, Vol. 25 Issue 3, p18 

    Comments on the proposed solutions in the administration of drug safety by the U.S. Food and Drug Administration (FDA) in the country. Proposition of Sandra Kweder, an officer at the FDA, towards the power of the agency in giving warnings to drug labels; Benefits of the proposal of Kweder; View...

  • New bill would strengthen FDA's drug safety review efforts. Frederick, Jim // Drug Store News;4/23/2007, Vol. 29 Issue 6, p27 

    The article reports on the introduction of a legislation to further strengthen the Food and Drug Administration's (FDA) drug safety review process by two members of the House of Representatives in the U.S. Representatives Henry Waxman and Edward Markey are promoting their version of the...

  • The Other Safety Dilemma. Andrews, Michelle // U.S. News & World Report;10/15/2007, Vol. 143 Issue 13, p64 

    This article describes drug safety and new legislation that will make it easier for the U.S. Food & Drug Administration (FDA) to keep dangerous products off the market. The law, signed in September 2007, grants the FDA the power to identify safety issues and force manufactures to adjust labels...

  • Risk evaluation and mitigation strategies: Challenges and opportunities for health-system pharmacists. Stubbings, JoAnn; Joshi, Rutu A.; Hoffman, James M. // American Journal of Health-System Pharmacy;9/15/2010, Vol. 67 Issue 18, p1547 

    In this article the authors discuss the aspects of Risk Evaluation and Mitigation Strategy program (REMS) of the U.S. Food and Drug Administration (FDA). They present information on development, function and organizational structure of REMS. They also discuss the effect of REMS on pharmaceutical...

  • Open Season on FDA. Wechsler, Jill // Pharmaceutical Executive;Mar2008, Vol. 28 Issue 3, p26 

    The article reports that U.S. legislators have raised concerns to pharmaceutical industries and to the Food and Drug Administration (FDA) concerning drug safety and loss of valuable information from clinical trials. Thus, Senator Edward Kennedy has asked Government Accountability Office (GAO) to...

  • Acronymics Anonymous (AA). Ross, Warren // Medical Marketing & Media;Aug2006, Vol. 41 Issue 8, p118 

    The article comments on the initiative of the U.S. Food and Drug Administration in launching a nationwide educational campaign aimed at reducing medication mix-ups caused by the use of abbreviations. The author stressed that most abbreviations are spelled out when first used. New Medicare drug...

  • Top 10 Arthritis Events of 2007? Axtell, Beth // Arthritis Today;Mar/Apr2008, Vol. 22 Issue 2, p104 

    The article outlines the Arthritis Foundation's top ten arthritis events of 2007. A legislation proposed by the U.S. Food and Drug Administration governing drug safety studies has been passed. The direct and indirect costs of arthritis in the U.S. have been quantifies, which include the...

  • Report from: China. Wan, Jane // Pharmaceutical Technology;Aug2010, Vol. 34 Issue 8, p18 

    The article reports on the request of the U.S. House of Representative addressed to the Food and Drug Administration (FDA) in ensuring heparin safety in China. Accordingly, the House assigned FDA to conduct inspection and ensuring the good quality of heparin in the said country. Moreover, the...

  • Critics Press FDA to Act on Evidence of Rosiglitazone's Cardiac Safety Issues. Mitka, Mike // JAMA: Journal of the American Medical Association;6/16/2010, Vol. 303 Issue 23, p2341 

    In this article, the author discusses the oversight of the U.S. Food and Drug Administration (FDA) over safety issues surrounding the rosiglitazone drug as of June 16, 2010. Critics reference findings from several meta-analyses and observational studies which showed that the drug is associated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics